Allarity (ALLR) Therapeutics announced that the European Patent Office, EPO, has issued a formal notice of its intention to grant a patent for Allarity’s Drug Response Predictor, DRP, companion diagnostic specific to stenoparib, the Company’s dual-targeted PARP/Tankyrase inhibitor. This patent represents a significant step forward in securing Allarity’s market position for stenoparib and the Stenoparib DRP companion diagnostic, which identifies patients most likely to derive clinical benefit from stenoparib treatment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLR:
- Allarity regains compliance with NASDAQ minimum bid price requirement
- ALLR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Allarity names Jeremy Graff as president, CDO, Jose Iglesias as consultant CMO
- Allarity Therapeutics Strengthens Leadership for Cancer Programs
- Allarity Therapeutics Nears Regulatory Approval with Stenoparib Trial Success
Questions or Comments about the article? Write to editor@tipranks.com